Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs Sana Biotechnology Inc (SANA) Price & Performance

Elastic NVTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs Sana Biotechnology Inc — how do they compare? Elastic NV trades at $62.42 (market cap $6.47B), while Sana Biotechnology Inc trades at $3.33 (market cap $987.94M). The key difference: Elastic NV is far larger — about 6.5× Sana Biotechnology Inc's market cap, and Elastic NV is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

ESTCSANA
Market Cap
$6.47B$987.94M
Sector
TechnologyHealth
52-Week High
$94.47$5.92
52-Week Low
$43.30$2.68
Enterprise Value
$5.69B$962.13M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.

Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA